DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB)

被引：37
|
作者：
Chapple, C. [1 ]
Wyndaele, J. J. [2 ]
Van Kerrebroeck, P. [3 ]
Radziszewski, P. [4 ]
Dvorak, V. [5 ]
Boerrigter, P. [6 ]
机构：
[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[2] Univ Antwerp, Fac Med, B-2020 Antwerp, Belgium
[3] Univ Med Ctr Maastricht, Maastricht, Netherlands
[4] Med Univ Warsaw, Dept Urol, Warsaw, Poland
[5] Private Obstet Gynecol Clin, Brno, Czech Republic
[6] Astellas Pharma, Med & Clin Dev, Global Dev EU, Leiderdorp, Netherlands
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2010年 / 9卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(10)60758-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [1] Pharmacological profile of mirabegron (YM178), a novel β3-adrenoceptor (AR) agonist
    Sato, Shuichi
    Ukai, Masashi
    Takasu, Toshiyuki
    Watanabe, Mai
    Someya, Akiyoshi
    Yanai, Hiroko
    Ohtake, Akiyoshi
    Ueshima, Koji
    Suzuki, Masanori
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 155P - 155P
  • [2] A NOVEL β3-ADRENOCEPTOR AGONIST MIRABEGRON FOR OVERACTIVE BLADDER SYMPTOMS
    Okada, Hiroshi
    Sato, Ryo
    Nishio, Kojiro
    Kawaguchi, Makoto
    Soh, Shigehiro
    Arai, Gaku
    JOURNAL OF UROLOGY, 2013, 189 (04): : E564 - E564
  • [3] Effects of mirabegron (YM178), a novel β3-adrenoceptor agonist, on non-micturition bladder contractions in conscious rats with bladder outlet obstruction (BOO)
    Ukai, Masashi
    Someya, Akiyoshi
    Nakata, Mari
    Ohtake, Akiyoshi
    Ueshima, Koji
    Suzuki, Masanori
    Watanabe, Mai
    Yanai, Hiroko
    Sato, Shuichi
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 155P - 155P
  • [4] Mirabegron the first 3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies
    Chapple, Christopher
    BJU INTERNATIONAL, 2014, 113 (06) : 847 - 848
  • [5] EFFECTS OF MIRABEGRON (YM178), A NOVEL BETA3-ADRENOCEPTOR AGONIST, ON THE PRIMARY BLADDER AFFERENT ACTIVITY OF THE RAT
    Aizawa, N.
    Homma, Y.
    Igawa, Y.
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (06) : 1018 - 1019
  • [6] A phase II dose-ranging study of mirabegron in patients with overactive bladder
    Christopher R. Chapple
    Vladimir Dvorak
    Pjotr Radziszewski
    Philip Van Kerrebroeck
    Jean Jacques Wyndaele
    Brigitte Bosman
    Peter Boerrigter
    Ted Drogendijk
    Arwin Ridder
    Ingrid Van Der Putten-Slob
    Osamu Yamaguchi
    International Urogynecology Journal, 2013, 24 : 1447 - 1458
  • [7] Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder
    Angulo, J. C.
    Khullar, V.
    Nitti, V. W.
    Siddiqui, E.
    ACTAS UROLOGICAS ESPANOLAS, 2013, 37 (10): : 640 - 651
  • [8] A phase II dose-ranging study of mirabegron in patients with overactive bladder
    Chapple, Christopher R.
    Dvorak, Vladimir
    Radziszewski, Pjotr
    Van Kerrebroeck, Philip
    Wyndaele, Jean Jacques
    Bosman, Brigitte
    Boerrigter, Peter
    Drogendijk, Ted
    Ridder, Arwin
    Van der Putten-Slob, Ingrid
    Yamaguchi, Osamu
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2013, 24 (09) : 1447 - 1458
  • [9] MIRABEGRON (YM178), A NOVEL β3-ADRENOCEPTOR (AR) AGONIST, INCREASED FUNCTIONAL BLADDER CAPACITY AND DECREASED MICTURITION FREQUENCY IN CONSCIOUS WATER-LOADED CYNOMOLGUS MONKEYS
    Someya, A.
    Ukai, M.
    Yanai, H.
    Watanabe, M.
    Ohtake, A.
    Ueshima, K.
    Suzuki, M.
    Sato, S.
    Sasamata, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 111 - 111
  • [10] Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder
    Eltink, Charlotte
    Lee, Jennifer
    Schaddelee, Marloes
    Zhang, Wenhui
    Kerbusch, Virginie
    Meijer, John
    van Marle, Sjoerd
    Grunenberg, Nicole
    Kowalski, Donna
    Drogendijk, Ted
    Moy, Selina
    Iitsuka, Hiromi
    van Gelderen, Marcel
    Matsushima, Hiroshi
    Sawamoto, Taiji
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (11) : 838 - 849
12345